Seven months after California launched the first state-branded prescription drug label in the country, health officials say more than 120,000 five-pen packs of CalRx insulin glargine have been distributed at a suggested retail price of $55. What the state cannot say is how many of those packs reached a patient. It does not track dispensing.
That gap is the clearest available measure of a program that has moved product into the supply chain faster than it has moved insulin into households. Reporting by KFF Health News found a pharmacist at a San Francisco Walgreens stocking two boxes of the state's pens without having dispensed any. Pharmacist Margaret On said keeping them on hand was worthwhile because "it's good to have if a patient comes in and doesn't have health insurance."
For the Californians the program was designed to reach, that distinction matters. Availability on a shelf is not the same as a filled prescription, and the difference is usually decided by insurance design rather than by price.
Distribution Is Not the Same Thing as a Filled Prescription
The pricing is real and unusually transparent. CalRx insulin glargine sells to pharmacies at $45 and carries a suggested retail price of no more than $55 for a five-pack of 3 mL pens, roughly $11 per pen. The state compares that to the $89 to $411 that popular brand names charge before retail markups or consumer discounts, and notes cash prices above $300 per vial elsewhere in the market. The product is an interchangeable biosimilar to Lantus, made available through a white-label agreement secured with Biocon Biologics by the nonprofit manufacturer Civica.
Elizabeth Landsberg, director of the Department of Health Care Access and Information, has framed the initiative around transparency, saying the state is "committed to transparent pricing, eliminating hidden costs, and ensuring equitable medication access for uninsured, underinsured, and vulnerable residents across our state."
Landsberg has said the state is working to get more insurers to cover the product and to place it in more pharmacies, and that reaching distribution agreements with three major pharmaceutical wholesalers was meaningful in itself. Four payers have added it to their formularies so far: Anthem Blue Cross, Blue Shield of California, the Valley Health Plan covering Santa Clara County employees, and the Federal Employees Health Benefits Program. The product is currently sold through Amazon and Costco as well as some CVS, Walgreens, and Walmart pharmacies.
Insurance Design Can Steer Patients Away from the Cheaper Product
The mechanics here are counterintuitive, and they explain much of the shortfall. A patient with commercial insurance and a $35 insulin copay cap has no financial reason to seek out a $55 cash product. A patient whose plan lists a different insulin on a preferred tier may find that the pharmacy automatically substitutes that product. A patient on Medicare Part D is already covered by a federal cap on insulin cost-sharing.
That leaves a narrower group for whom CalRx changes the arithmetic: uninsured residents, people between coverage, those with high deductible plans early in the plan year, and anyone needing an emergency supply. California's insulin copay law, which caps cost-sharing at $35 for a month's supply in state-regulated plans, took effect for large group plans at the start of this year and will apply to individual and small group plans next year. It broadened protection while simultaneously shrinking the population for whom a $55 cash option is the best available deal.
Pharmacy stocking behavior follows demand. If a pharmacist rarely sees a patient who benefits, the boxes sit, and a product that sits is a product a buyer eventually stops reordering. That feedback loop is the practical risk to a program whose value depends on being physically present when an uninsured patient walks in without warning. State analysts previously warned that California's entry into the insulin market could prompt other manufacturers to adjust availability, a possibility officials said they would monitor.
Uninsured Californians Are the Group the Program Was Built For
Roughly 3.7 million California adults have been diagnosed with diabetes. Surveys have repeatedly found that a meaningful share of insulin users skip or stretch doses because of cost, and rationing carries documented consequences, including diabetic ketoacidosis and hospitalization.
The people most likely to benefit are those without coverage, those with lapsed coverage, agricultural and gig workers, recent immigrants who face eligibility restrictions, and residents in rural counties where fewer pharmacies stock specialty products. Anyone traveling without their supplies also falls into this group. Notably, the state has said a new prescription is not required to switch, since the product is interchangeable with Lantus and a pharmacist can substitute it directly.
The program's own footprint has narrowed in one respect. A $50 million allocation for in-state manufacturing was eliminated as a budget-saving measure, and fill-and-finish work now happens at a Civica facility in Virginia. Civica continues developing its own interchangeable biosimilar insulin glargine and a rapid-acting insulin under the CalRx label.
Steps Patients Can Take at the Pharmacy Counter
Patients who think they qualify should start by asking a pharmacist directly whether the pharmacy stocks the state-labeled product and, if not, whether it can be ordered. Cash-paying patients should compare the $55 price against the pharmacy's own cash price and any discount card price for the same molecule, because the cheapest option varies.
Insured patients should ask what their plan's insulin copay actually is before assuming a cash purchase is cheaper, since a capped copay may be less than $55. Anyone considering a switch between insulin products should confirm with a prescriber or pharmacist that the substitution is appropriate, and no one should ration or stop insulin due to cost without first asking about patient assistance programs, community health center pricing, or emergency supply provisions.
What remains unmeasured is the central question. Because the state does not track dispensing, there is no public figure for how many patients have actually used CalRx insulin, and 120,000 packs distributed could represent widespread use or largely unsold inventory. Officials have said they are working to expand insurer coverage and pharmacy placement, and MedicalDaily has covered how formulary decisions shape what patients pay. A dispensing metric would settle the question, and until one exists, the program's reach is a matter of inference rather than evidence.
Key Questions Answered
What is CalRx insulin? It is insulin glargine sold under California's state prescription drug label at a suggested retail price of no more than $55 for a five-pen pack, roughly $11 per pen.
Is it the same as brand-name insulin? It is an interchangeable biosimilar to Lantus, produced through an agreement involving the nonprofit manufacturer Civica and Biocon Biologics.
How many patients have used it? That figure is not public. The state says more than 120,000 packs have been distributed but does not track how many were dispensed to patients.
Who benefits most from the price? Uninsured residents, people between coverage, patients early in a high-deductible plan year, and anyone needing an emergency supply. Insured patients may already have a lower capped copay.
Where can it be purchased? Through Amazon and Costco, and at some CVS, Walgreens, and Walmart pharmacies. Other pharmacies may be able to order it.
Do I need a new prescription to switch? The state has said a new prescription is not required because the product is interchangeable, but patients should confirm the substitution with a pharmacist or prescriber.
What should I do if I cannot afford insulin right now? Ask a pharmacist about the state product, manufacturer patient assistance programs, and community health center pricing. Do not ration or stop insulin without medical guidance.
